osteoporosis
OSTEOPOROSIS
Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.

Definition

  • Progressive, systemic skeletal disease characterized by decreased bone mass & micro-architectural deterioration of bone tissue leading to increased bone fragility & susceptibility to fractures
    • Bone strength, reflecting both density & quality of the bone, is compromised thus increasing fracture risk
    • Fractures commonly occur in the hip, spine & wrist with the hip fractures having a high morbidity
  • Common presentations: Back pain, low-trauma fracture, height loss, increasing dorsal kyphosis
  • Though osteoporosis in Asia is very much underdiagnosed & undertreated, it is projected that by 2050, >50% of osteoporotic hip fractures will happen in Asia
    • In most developing countries, dual energy X-ray absorptiometry (DXA) is expensive & is widely unavailable particularly in the rural areas
  • Calcium intake in almost all Asian countries is below the FAO/WHO recommendations of 1-1.3 g/day
  • Studies done in both sexes & all age groups in different Southeast Asian countries demonstrated widespread incidence of vitamin D deficiency or insufficiency

Risk Factors

Risk Factors in Women for Fracture & Osteoporosis
The more risk factors that are present, the greater the risk of fracture
Non-modifiable
  • Previous history of fracture as an adult
  • History of osteoporotic hip fracture in 1st-degree relative
  • Advanced age [low body weight & older age (Osteoporosis Self-Assessment Tool for Asians - OSTA)]
  • Poor health/frailty
  • Ethnic group (Asians generally have lower risk compared to Caucasians)
  • Early natural or surgical menopause before 45 year of age or prolonged premenopausal amenorrhea >1 year
  • Genetic diseases: Cystic fibrosis, osteogenesis imperfecta, Ehlers-Danlos, hemochromatosis, Marfan syndrome
Modifiable
  • Recurrent falls
  • Decreased body weight (<57.6 kg [<127 lbs])
  • Impaired vision
  • Medical conditions: Rheumatoid arthritis, estrogen deficiency, Vitamin D deficiency due to lack of sunlight exposure or low intake, thyrotoxicosis, or prolonged Levothyroxine intake
  • Cigarette smoking
  • Excessive alcohol & caffeine intake (≥3 drinks/day)
  • Low calcium (Ca) intake, excessive salt & Vitamin A intake
  • Oral glucocorticoid use ≥5 mg/day of prednisone for ≥3 month
  • Sedentary lifestyle (lack of physical activity)
  • Secondary osteoporosis
  • Lack of sun exposure
Risk Factors in Men for Fracture & Osteoporosis
  • Non-traumatic fractures of the hip, vertebrae or wrist
  • Prior osteoporotic fracture from age 50 years
  • Hypogonadism, growth hormone deficiency
  • Idiopathic hypercalciuria
  • Hyperparathyroidism
  • Rheumatoid arthritis
  • Lymphoma, multiple myeloma
  • Hyperthyroidism
  • Oral glucocorticoid use ≥5 mg/day of Prednisone for ≥3 months
  • Physical inactivity
  • Low body mass index (kg/m2)
  • Anticonvulsants (eg Phenytoin, Phenobarbital)
  • Smoking
  • Alcohol intake (≥3 drinks/day)

Factors Associated with Glucocorticoid-Induced Osteoporosis (GIOP) or Fractures

  • Low bone density
  • Cumulative steroid dose
  • Age >65 years
  • BMI ≤20 kg/m2
  • Smoking, excessive alcohol use
  • Diseases associated with low bone density (eg rheumatoid arthritis, inflammatory bowel disease), sex hormone deficiency, family history of osteoporosis, history of fracture & immobilization
Using FRAX™ score to categorize patient's risk, treatment is recommended for postmenopausal women with:
  • Low risk of fracture (<100%) & intake of  ≥75 mg daily of Prednisolone or its equivalent for >3 months
  • Medium risk of fracture (10-20%) & intake of glucocorticoid at any dose for >3 months
  • High risk of fracture (>20%) & intake of glucocorticoid at any dose for any length of time
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
13 Apr 2018
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
15 Apr 2018
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.